Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Primary Malignant Peritoneal Mesothelioma Mimicking Peritoneal Carcinomatosis on F-18 FDG PET/CT

F-18 FDG PET/CT에서 복막 암종증과 유사한 원발성 복막 악성 중피종

  • Kim, Jin-Suk (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Lim, Seok-Tae (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Jeong, Young-Jin (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Kim, Dong-Wook (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Jeong, Hwan-Jeong (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital) ;
  • Sohn, Myung-Hee (Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital)
  • 김진숙 (전북대학교 의학전문대학원 핵의학교실) ;
  • 임석태 (전북대학교 의학전문대학원 핵의학교실) ;
  • 정영진 (전북대학교 의학전문대학원 핵의학교실) ;
  • 김동욱 (전북대학교 의학전문대학원 핵의학교실) ;
  • 정환정 (전북대학교 의학전문대학원 핵의학교실) ;
  • 손명희 (전북대학교 의학전문대학원 핵의학교실)
  • Published : 2009.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Malignant mesothelioma of the peritoneum is a rare neoplasm with a rapidly fatal course. The tumour arises from the mesothelial cells lining the pleura and peritoneum or, rarely, in the pericardium or tunica vaginalis. This neoplasm is characterized by being difficult to diagnose, having a rapid evolution and a poor response to therapy. Mesothelioma is very glucose avid, and malignant pleural mesothelioma has been reported concerning the utility of F-18 FDG PET or PET/CT. But little has been known about the imaging finding of malignant peritoneal mesothelioma on F-18 FDG PET/CT. We report a case of malignant peritoneal mesothelioma mimicking peritoneal carcinomatosis of F-18 FDG PET/CT.

Keywords

References

  1. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003
  2. Tandar A, Abraham G, Gurka J, Wendel M, Stolbach L. Recurrent peritoneal mesothelioma with long-delayed recurrence. J Clin Gastroenterol 2001;33:247-50 https://doi.org/10.1097/00004836-200109000-00018
  3. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 1985;24:293-328
  4. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53 https://doi.org/10.1200/JCO.1988.6.1.147
  5. Neumann V, Rutten A, Scharmach M, Muller KM, Fischer M. Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health 2004;77:191-9 https://doi.org/10.1007/s00420-003-0498-6
  6. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269-73
  7. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province (Soufu Africa). Br J Ind Med 1960;17:260
  8. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 1981;75:311-3
  9. Sheila Sheth, MD, Karen M. Horton, MD. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003;23:458-73
  10. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol 2002;29:51-61 https://doi.org/10.1053/sonc.2002.37377
  11. Simsek H, Kadayifci A, Okan E. Importance of serum CA-125 levels in malignant peritoneal mesothelioma. Tumor Biol 1996;17:1-4
  12. Duan HJ, Itoh N, Tamagami O, Katsuyama T, Shigematus H. Diffuse malignant peritoneal mesothelioma in a young women with a high serum level of CA-125. Acta Pathol Jpn 1991;41:158-63
  13. Hamrick-Tumerr JE, Chiechi MV, Abbitt PL, Ros PR. Neoplastic and inflammatory processes of the peritoneum, omentum, and mesentery: diagnosis with CT. Radiographies 1992;12:1051-68 https://doi.org/10.1148/radiographics.12.6.1439011
  14. James M. Busch, Jonathan B. Kruskal, Bryan Wu. Best cases from the AFIP: malignant peritoneal mesothelioma. Radiographies 2002;22:1511-5 https://doi.org/10.1148/rg.226025125
  15. Yamamoto M, Gerbaudo VH, Gill RR, jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Rad 2007;64;356-66 https://doi.org/10.1016/j.ejrad.2007.08.010
  16. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco K, Larson SM, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-8 https://doi.org/10.1016/j.jtcvs.2006.03.068
  17. Banayan S, Hot A, Janier M, Ninet J, Zurlinden O, Billotey C. Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by $^{18}F$-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:751 https://doi.org/10.1007/s00259-005-0059-1
  18. Eade TN, Fulham MJ, Constable CJ. Primary malignant peritoneal mesothelioma: appearance on F-18 FDG positron emission tomographic images. Clin Nucl Med 2002;27:924-5 https://doi.org/10.1097/00003072-200212000-00029